Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy

Purpose: We determined the impact of preexisting co-morbidities on survival of men with clinical stages T1b and T2NXM0 prostate cancer treated with surgery or radiation therapy, Materials and Methods: A weighted co-morbidity score was determined for 276 consecutive men treated with surgery (138) or radiation therapy (138) at a Veterans Affairs medical center and was correlated with actuarial freedom from death due to co-morbid disease. Results: After a median potential followup of 7.0 years 91 patients (33%) died of co-morbid disease and 20 (7%) died of cancer related causes. There were highly significant correlations between actuarial survival and weighted co-morbidity (p<0.000001), and the 10-year actuarial survivals in men with no or severe co-morbidities acre 66 and 9%, respectively. Associations between patient age and co-morbidity score were highly significant (p<0.0001). The age adjusted risk of co-morbid death was 5.7 times greater in men with severe compared to no co-morbidities.. There were also significant correlations between actuarial survival and weighted co-morbidity among patients treated with surgery (p=0.02) and radiation therapy (p=0.0002). Patient age and severity of co-morbidities were significantly greater among men treated with radiation therapy compared to surgery, and age adjusted risk of co-morbid death among men with a co-morbidity score of 1 was 3.8 times greater among men treated with radiation therapy (p=0.025). Conclusions: Cancer related deaths are unusual within 5 to 10 Sears after surgery or radiation therapy in men with stages T1b and 2 prostate cancer, The risk of death during this interval is directly related to the severity of co-morbid conditions, which should be factored in an individual when assessing the advisability of therapeutic intervention. Since patient co-morbidities impact all cause survival, quantitative assessment of co-morbidities using validated instruments offers a method to control partially for the variabilities of health status among men receiving different treatments for localized prostate cancer.